Optimizing Treatment for First-Episode Psychosis in Women

Choosing the right antipsychotic choice for females experiencing their first episode of psychosis (FEP) is vital for long-term health. Traditional guidelines often lack sex-specific details. However, women face higher risks of hyperprolactinemia and metabolic issues. These side effects cause significant distress and impact medication adherence. Therefore, a multidisciplinary panel developed new recommendations to address these unique needs. Specifically, the panel prioritized safety profiles over traditional prescribing habits.

Evidence-Based Antipsychotic Choice for Females

Many common medications, such as olanzapine and risperidone, pose significant risks for female patients. Instead, the guideline recommends aripiprazole as the primary first-line treatment. This medication effectively manages symptoms without causing severe hormonal or metabolic shifts. Notably, shared decision-making ensures that patients and doctors select the most appropriate therapy together. Moreover, clinicians must consider the long-term physical risks associated with weight gain and endocrine disruption. Adopting a sex-sensitive approach improves treatment equity and long-term recovery outcomes.

Guideline Recommendations and Implementation

Clinicians should avoid using medicines with high prolactin-elevation risks as first-line options for females. This list includes amisulpride, paliperidone, and most first-generation antipsychotics. Additionally, doctors should utilize shared decision-making tools for both adults and adolescents. These tools help balance therapeutic efficacy with individual safety concerns. Furthermore, regular monitoring of cardiometabolic markers and prolactin levels remains essential. Consequently, following these guidelines will lead to safer prescribing and better patient satisfaction.

Frequently Asked Questions

Why is aripiprazole the preferred antipsychotic choice for females?

Aripiprazole is preferred because it has a consistently favorable profile regarding prolactin levels and cardiometabolic health compared to other second-generation antipsychotics.

What are the risks of using olanzapine or risperidone in women?

These medications are associated with higher risks of significant weight gain, metabolic syndrome, and hyperprolactinemia, which can lead to menstrual irregularities and long-term health issues.

How does sex-sensitive prescribing impact FEP outcomes?

By minimizing distressing side effects, sex-sensitive prescribing improves treatment acceptability and adherence, which are critical for preventing relapse in first-episode psychosis.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

Hynes-Ryan C et al. Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis. Schizophr Bull. 2026 Mar 07. doi: undefined. PMID: 41793755.

Seeman MV. Antipsychotic treatment for women with schizophrenia. Expert Rev Neurother. 2021;21(7):791-807.

Cooper D et al. Antipsychotic-induced hyperprolactinaemia: synthesis of world-wide guidelines. Lancet Psychiatry. 2017;4(2):153-163.